Previous 10 | Next 10 |
HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing ...
A South Korean research team has discovered a novel brain scan technique that has the potential to revolutionize glioblastoma diagnosis and treatment. Led by Severance Hospital’s Professor Yun Mijin and Director C. Justin Lee from the Center for Cognition and Sociality, the research the ...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed a biotech veteran to its board of directors. The company announced that Amy Mahery, a high...
Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunology HOUSTON, TX / ACCESSWIRE / January 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)...
HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced completi...
2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...
A new multidisciplinary consortium is combining knowledge from several different disciplines to develop new methods for diagnosing and treating gliomas. Comprised of Sweden’s Umeå University and Umeå University Hospital and PSE Data Security from Switzerland, the consortium wil...
A biomedical researcher from Spain has spent the past several years working on a novel brain-tumor treatment that would expand the boundaries of medical innovation to unseen territories. Dr. Marta Alonso shifted her focus to pediatric brain tumors after she met a teenager with medulloblastoma a...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced a recommendation from the independent Data Safety Monitoring Board (“DSMB”) rega...
Independent DSMB recommends continuing clinical trial of Berubicin without modification Enrollment expected to be complete in early Q1 2024 HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (CNS or the Company), a biopharmaceutical company specia...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NYSE Market:
Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACC...
Scientists from the University of Florida in America have designed a new vaccine for cancer that prompts the immune system to target glioblastoma. Glioblastoma is an aggressive type of cancer that forms in the spinal cord and/or brain. Roughly 19,000 people in the European Union are afflicted...